login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
RAPPORT THERAPEUTICS INC (RAPP) Stock News
USA
- NASDAQ:RAPP -
US75383L1026
-
Common Stock
25.66
USD
+0.3 (+1.18%)
Last: 11/7/2025, 8:11:14 PM
25.66
USD
0 (0%)
After Hours:
11/7/2025, 8:11:14 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RAPP Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data
3 days ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
3 days ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
3 days ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics to Participate in Upcoming Investor Conferences
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
2 months ago - By: Benzinga
- Mentions:
ACTU
CAMP
GNPX
PMVP
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Pricing of Public Offering of Common Stock
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Pricing of Public Offering of Common Stock
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Proposed Public Offering of Common Stock
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Proposed Public Offering of Common Stock
2 months ago - By: Benzinga
- Mentions:
NBY
MEIP
SMMT
TLPH
...
12 Health Care Stocks Moving In Monday's Intraday Session
2 months ago - By: Investor's Business Daily
- Mentions:
PFE
Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures
2 months ago - By: Stocktwits
- Mentions:
IWMW
UWM
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
2 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
3 months ago - By: The Motley Fool
Rapport (RAPP) Q2 Net Loss Widens 47%
3 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
3 months ago - By: Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Please enable JavaScript to continue using this application.